2021 Webinar: Use of Serum and Imaging Biomarkers of NAFLD/NASH in Clinical Practice-Use of Serum and Imaging Biomarkers of NAFLD/NASH in Clinical Practice

Video Transcription

Video Summary

The webinar discussed the use of serum and imaging biomarkers in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The speakers highlighted the need for biomarkers that can be used to accurately diagnose and stage liver fibrosis, predict disease progression, assess treatment response, and stratify risk in at-risk populations. The use of serum-based biomarkers, such as FIB-4 and ELF score, were discussed for the staging of liver fibrosis and predicting prognosis. The limitations of these tests, including the need for sequential testing and the risk of false positive results, were also mentioned. Imaging biomarkers, such as FibroScan and MRE, were discussed for their ability to provide liver stiffness measurements and detect fibrosis. The speakers emphasized the importance of considering the context of use when choosing biomarkers, as well as the need for further research to validate and integrate biomarker testing into clinical practice. While there is potential for biomarkers to serve as surrogate endpoints for histology in the future, more studies are needed to establish their clinical utility and link them to clinical outcomes. Overall, the webinar highlighted the potential of serum and imaging biomarkers in improving the diagnosis and management of NAFLD and NASH.

Asset Caption

Presenters: Emmanuel A. Tsochatzis, MD, PhD, MSc, FEBTM, FRCP, Mohammad Shadab Siddiqui, MD and Alina M. Allen, MD
Moderator: Kathleen E. Corey, MD, MPH, MMSc

Keywords

serum

imaging biomarkers

non-alcoholic fatty liver disease

NAFLD

non-alcoholic steatohepatitis

NASH

liver fibrosis

disease progression

treatment response

risk stratification